Region Gotland

The medical center is at the forefront of tackling multidrug-resistant infections, particularly focusing on urinary tract infections caused by extended spectrum beta-lactamases-producing Enterobacterales. Through innovative research, the center aims to identify alternative oral antibiotic regimens that are safe and effective, reducing reliance on traditional treatments like ciprofloxacin and trimethoprim-sulfamethoxazole.

• Alternative antibiotic therapies
• ESBL-producing Enterobacterales
• Non-inferiority trials

This research contributes significantly to global efforts in combating antibiotic resistance, offering new hope for patients with complex infections.

Specializing in complement-mediated renal diseases, the center is pioneering studies on C3 glomerulopathy. By evaluating the efficacy of aliskiren, a direct renin inhibitor, the center seeks to innovate treatment protocols that reduce complement activation in the kidneys, potentially stabilizing or improving kidney function compared to traditional ACE inhibitors like enalapril.

• Renin inhibitors
• Complement activation
• Renal biopsy analysis

These advancements are crucial in developing targeted therapies that address the underlying mechanisms of renal diseases.

The center is advancing the treatment of heart failure with preserved ejection fraction (HFpEF) through the SPIRRIT-HFpEF trial. This research evaluates the impact of initiating spironolactone or eplerenone alongside standard care, aiming to reduce heart failure hospitalizations and cardiovascular mortality.

• Heart failure management
• Spironolactone and eplerenone
• Registry-based Randomized Clinical Trials

By integrating these findings into clinical practice, the center enhances patient outcomes in heart failure management.

Focusing on early type 2 diabetes, the center is exploring the benefits of SGLT2 inhibitors compared to metformin. The SMARTEST trial aims to determine the efficacy of these treatments in promoting progression-free survival, offering insights into optimal therapeutic strategies for diabetes management.

• SGLT2 inhibitors vs. metformin
• Progression-free survival
• Early intervention strategies

This research is pivotal in shaping future guidelines for diabetes care, emphasizing early and effective intervention.